Focal Segmental Glomerulosclerosis Market

Focal Segmental Glomerulosclerosis Market (Disease Type: Primary Focal Segmental Glomerulosclerosis and Secondary Focal Segmental Glomerulosclerosis; and Disease Management: Diagnosis and Treatment) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Focal Segmental Glomerulosclerosis Market Outlook 2031

  • The global industry was valued at US$ 538.5 Mn in 2022
  • It is estimated to advance at a CAGR of 6.5% from 2023 to 2031 and reach US$ 956.2 Mn by the end of 2031

Analyst Viewpoint

Increase in prevalence of kidney infection is one of the key factors boosting the global focal segmental glomerulosclerosis market size. A person suffering from kidney disease is at higher risk of contracting focal segmental glomerulosclerosis, as both kidney diseases and focal segmental glomerulosclerosis are interrelated. Advancements in R&D are also augmenting the focal segmental glomerulosclerosis industry growth. Various treatments are being developed for focal segmental glomerulosclerosis, including stem cell therapy and genetic therapies.

Companies in the global landscape are striving to develop specialized diagnostic tests and treatments to improve the prognosis of patients with this disease. In line with the latest focal segmental glomerulosclerosis market, key players are also engaged in product launches and product approvals to increase their industry share.

Focal Segmental Glomerulosclerosis Market

Market Introduction

Focal segmental glomerulosclerosis (FSGS) is a type of kidney disease characterized by the formation of scar tissue on the glomeruli, the filtering part of the kidney that eliminates waste from the body.

FSGS causes aberrant protein loss in the urine and impairment in the kidneys' filtration capacity. The condition is most commonly characterized by frothy urine, excessive water retention, infection susceptibility, and fatty casts in the urine.

Some of the common causes of FSGS are kidney diseases, obesity, excessive intake of drugs or steroids, and inherited genetic issues. The condition affects men more than women. People with FSGS may also gain weight due to high blood fat levels. Furthermore, they may experience low appetite, exhaustion, and the accumulation of extra fluid in the body.

A combination of imaging studies and laboratory tests are usually used to diagnose FSGS. CT scan or ultrasound helps in detecting any abnormalities and impairment in the kidneys.

Laboratory tests are performed to check the levels of high creatinine, while a urine test helps diagnose proteinuria. Additionally, renal biopsy may be necessary to confirm FSGS in patients. This procedure involves taking a small sample of the kidney with a specific needle and examining it under a microscope.

Increase in Prevalence of Kidney Infection Fueling Focal Segmental Glomerulosclerosis Market Demand

Kidney infection is a type of urinary tract infection (UTI) that may begin in a different part of the urinary tract, such as the urethra (tube that carries urine from the body) or bladder, and travel to one or both kidneys.

According to the Centers for Disease Control and Prevention, around 37 million Americans or about 15% of the population in the U.S. is estimated to suffer from chronic kidney disease. In 2021, the frequency was 6% among those between the ages of 18 and 44, and 12% among those between the ages of 45 and 64. Thus, increase in incidence of kidney infections is one of the key focal segmental glomerulosclerosis market drivers.

Rise in Healthcare Expenditure Boosting Market Progress

Growth in spending capacity on healthcare is aiding in the creation and accessibility of medications for focal segmental glomerulosclerosis. Rise in funding for clinical trials and research, which enhance the production of new drugs, is also augmenting the focal segmental glomerulosclerosis industry.

As per a report released in May 2023 by the Office for National Statistics, the U.K. Government agency, healthcare spending in the U.K. increased by 9.4% in nominal terms and 9.7% in real terms between 2020 and 2021. Additionally, the U.K. spent £280.7 Bn (US$ 367.25 Bn) on healthcare, £39.6 Bn (US$ 51.84 Bn) on pharmaceuticals, and £35.1 Bn (US$ 45.93 Bn) on preventative care in 2021-more than doubling the amount spent in 2020.

Thus, increase in healthcare spending is creating lucrative focal segmental glomerulosclerosis market opportunities for companies operating in the sector.

Regional Outlook

As per the latest focal segmental glomerulosclerosis market analysis, North America accounted for the largest share in 2022. Presence of developed economies, availability of modern medical facilities, and surge in adoption of high-end technology are driving the growth of the focal segmental glomerulosclerosis industry in the region.

As per focal segmental glomerulosclerosis market research, the U.S. constitutes significant share of the sector in North America. According to Evaluate Ltd., around 40,000 people in the U.S. were afflicted with FSGS in 2021.

Ongoing clinical trials by manufacturers and rise in research activities are anticipated to spur the market dynamics of North America. Majority of manufacturers worldwide are opting to conduct clinical trials and research in the U.S. owing to the favorable geographical position and governmental policies in the country.

Analysis of Key Players

Increase in investment in research and development activities is a prominent focal segmental glomerulosclerosis marketing strategy adopted by the leading players in the global landscape. Key players are also entering into partnership and collaboration agreements to expand their product portfolio.

Variant Pharmaceuticals, Inc., ChemoCentryx, Inc., Travere Therapeutics, AbbVie, Inc., Novartis AG, Pfizer, Inc., AstraZeneca plc., Sanofi S.A., GlaxoSmithKline plc., are Teva Pharmaceutical Industries Ltd. are the leading players operating in the global landscape.

Each of these firms have been profiled in the focal segmental glomerulosclerosis market report based on parameters such as company overview, business strategies, financial overview, business segments, product portfolio, and recent developments.

Key Developments

  • In May 2022, Travere Therapeutics announced that the U.S. Food and Drug Administration (FDA) had granted accelerated approval to FILSPARI (sparsentan) to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression
  • In September 2021, Vifor Pharma and Travere Therapeutics announced a joint collaboration and licensing agreement for the commercialization of sparsentan in Europe, Australia, and New Zealand. Sparsentan is a novel investigational product candidate that is being evaluated in pivotal phase-III clinical studies for the treatment of FSGS and IgAN, two rare progressive kidney disorders and leading causes of end-stage kidney disease.

Focal Segmental Glomerulosclerosis Market Snapshot

Attribute Detail
Market Size in 2022 US$ 538.5 Mn
Market Forecast (Value) in 2031 US$ 956.2 Mn
Growth Rate (CAGR) 6.5%
Forecast Period 2023-2031
Historical Data Available for 2017-2021
Quantitative Units US$ Mn for Value
Market Analysis It includes segment analysis as well as regional-level analysis. Furthermore, the qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces Analysis, value chain analysis, and key trend analysis.
Competition Landscape
  • Market share analysis by company (2022)
  • Company profiles section includes an overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy and recent developments, and key financials
Format Electronic (PDF) + Excel
Market Segmentation
  • Disease Type
    • Primary Focal Segmental Glomerulosclerosis
    • Secondary Focal Segmental Glomerulosclerosis
  • Disease Management
    • Diagnosis
      • Kidney Biopsy
      • Creatinine Test
      • Others
    • Treatment
      • Drug Therapy
      • Dialysis
      • Kidney Transplant
Regions Covered
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa
Countries Covered
  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Russia and CIS
  • Japan
  • China
  • India
  • ASIAN
  • Brazil
  • Mexico
  • GCC
  • South Africa
Companies Profiled
  • Variant Pharmaceuticals, Inc.
  • ChemoCentryx, Inc.
  • Travere Therapeutics
  • AbbVie, Inc.
  • Novartis AG
  • Pfizer, Inc.
  • AstraZeneca plc.
  • Sanofi S.A.
  • GlaxoSmithKline plc.
  • Teva Pharmaceutical Industries Ltd.
Customization Scope Available upon request
Pricing Available upon request

Frequently Asked Questions

How big was the focal segmental glomerulosclerosis market in 2022?

It was valued at US$ 538.5 Mn in 2022

How is the focal segmental glomerulosclerosis business expected to grow by 2031?

It is anticipated to grow at a CAGR of 6.5% from 2023 to 2031

What are the key factors driving the demand for focal segmental glomerulosclerosis?

Increase in prevalence of kidney infection and rise in healthcare expenditure

Which was the largest disease type segment in the largest focal segmental glomerulosclerosis industry in 2022?

The primary focal segmental glomerulosclerosis segment accounted for the largest share in 2022

Which was the major region in the global focal segmental glomerulosclerosis landscape in 2022?

North America was the leading region in 2022

Who are the key players in the focal segmental glomerulosclerosis field?

Variant Pharmaceuticals, Inc., ChemoCentryx, Inc., Travere Therapeutics, AbbVie, Inc., Novartis AG, Pfizer, Inc., AstraZeneca plc., Sanofi S.A., GlaxoSmithKline plc., and Teva Pharmaceutical Industries Ltd.

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Focal Segmental Glomerulosclerosis Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Disease Type Definition

            4.1.2. Industry Evolution/Developments

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Focal Segmental Glomerulosclerosis Market Analysis and Forecast, 2017–2031

    5. Key Insights

        5.1. Pipeline Analysis

        5.2. Key Disease Type/Brand Analysis

        5.3. Key Mergers & Acquisitions

        5.4. COVID-19 Pandemic Impact on Industry

    6. Global Focal Segmental Glomerulosclerosis Market Analysis and Forecast, by Disease Type

        6.1. Introduction & Definition

        6.2. Key Findings/Developments

        6.3. Market Value Forecast, by Disease Type, 2017–2031

            6.3.1. Primary Focal Segmental Glomerulosclerosis

            6.3.2. Secondary Focal Segmental Glomerulosclerosis

        6.4. Market Attractiveness Analysis, by Disease Type

    7. Global Focal Segmental Glomerulosclerosis Market Analysis and Forecast, by Disease Management

        7.1. Introduction & Definition

        7.2. Key Findings/Developments

        7.3. Market Value Forecast, by Disease Management, 2017–2031

            7.3.1. Diagnosis

                7.3.1.1. Kidney Biopsy

                7.3.1.2. Creatinine Test

                7.3.1.3. Others

            7.3.2. Treatment

                7.3.2.1. Drug Therapy

                7.3.2.2. Dialysis

                7.3.2.3. Kidney Transplant

        7.4. Market Attractiveness Analysis, by Disease Management

    8. Global Focal Segmental Glomerulosclerosis Market Analysis and Forecast, by Region

        8.1. Key Findings

        8.2. Market Value Forecast, by Region, 2017–2031

            8.2.1. North America

            8.2.2. Europe

            8.2.3. Asia Pacific

            8.2.4. Latin America

            8.2.5. Middle East & Africa

        8.3. Market Attractiveness Analysis, by Region

    9. North America Focal Segmental Glomerulosclerosis Market Analysis and Forecast

        9.1. Introduction

        9.2. Key Findings

        9.3. Market Value Forecast, by Disease Type, 2017–2031

            9.3.1. Primary Focal Segmental Glomerulosclerosis

            9.3.2. Secondary Focal Segmental Glomerulosclerosis

        9.4. Market Value Forecast, by Disease Management, 2017–2031

            9.4.1. Diagnosis

                9.4.1.1. Kidney Biopsy

                9.4.1.2. Creatinine Test

                9.4.1.3. Others

            9.4.2. Treatment

                9.4.2.1. Drug Therapy

                9.4.2.2. Dialysis

                9.4.2.3. Kidney Transplant

        9.5. Market Value Forecast, by Country, 2017–2031

            9.5.1. U.S.

            9.5.2. Canada

        9.6. Market Attractiveness Analysis

            9.6.1. By Disease Type

            9.6.2. By Disease Management

            9.6.3. By Country

    10. Europe Focal Segmental Glomerulosclerosis Market Analysis and Forecast

        10.1. Introduction

        10.2. Key Findings

        10.3. Market Value Forecast, by Disease Type, 2017–2031

            10.3.1. Primary Focal Segmental Glomerulosclerosis

            10.3.2. Secondary Focal Segmental Glomerulosclerosis

        10.4. Market Value Forecast, by Disease Management, 2017–2031

            10.4.1. Diagnosis

                10.4.1.1. Kidney Biopsy

                10.4.1.2. Creatinine Test

                10.4.1.3. Others

            10.4.2. Treatment

                10.4.2.1. Drug Therapy

                10.4.2.2. Dialysis

                10.4.2.3. Kidney Transplant

        10.5. Market Value Forecast, by Country/Sub-region, 2017–2031

            10.5.1. Germany

            10.5.2. U.K.

            10.5.3. France

            10.5.4. Italy

            10.5.5. Spain

            10.5.6. Rest of Europe

        10.6. Market Attractiveness Analysis

            10.6.1. By Disease Type

            10.6.2. By Disease Management

            10.6.3. By Country/Sub-region

    11. Asia Pacific Focal Segmental Glomerulosclerosis Market Analysis and Forecast

        11.1. Introduction

        11.2. Key Findings

        11.3. Market Value Forecast, by Disease Type, 2017–2031

            11.3.1. Primary Focal Segmental Glomerulosclerosis

            11.3.2. Secondary Focal Segmental Glomerulosclerosis

        11.4. Market Value Forecast, by Disease Management, 2017–2031

            11.4.1. Diagnosis

                11.4.1.1. Kidney Biopsy

                11.4.1.2. Creatinine Test

                11.4.1.3. Others

            11.4.2. Treatment

                11.4.2.1. Drug Therapy

                11.4.2.2. Dialysis

                11.4.2.3. Kidney Transplant

        11.5. Market Value Forecast, by Country/Sub-region, 2017–2031

            11.5.1. China

            11.5.2. Japan

            11.5.3. India

            11.5.4. Australia & New Zealand

            11.5.5. Rest of Asia Pacific

        11.6. Market Attractiveness Analysis

            11.6.1. By Disease Type

            11.6.2. By Disease Management

            11.6.3. By Country/Sub-region

    12. Latin America Focal Segmental Glomerulosclerosis Market Analysis and Forecast

        12.1. Introduction

        12.2. Key Findings

        12.3. Market Value Forecast, by Disease Type, 2017–2031

            12.3.1. Primary Focal Segmental Glomerulosclerosis

            12.3.2. Secondary Focal Segmental Glomerulosclerosis

        12.4. Market Value Forecast, by Disease Management, 2017–2031

            12.4.1. Diagnosis

                12.4.1.1. Kidney Biopsy

                12.4.1.2. Creatinine Test

                12.4.1.3. Others

            12.4.2. Treatment

                12.4.2.1. Drug Therapy

                12.4.2.2. Dialysis

                12.4.2.3. Kidney Transplant

        12.5. Market Value Forecast, by Country/Sub-region, 2017–2031

            12.5.1. Brazil

            12.5.2. Mexico

            12.5.3. Rest of Latin America

        12.6. Market Attractiveness Analysis

            12.6.1. By Disease Type

            12.6.2. By Disease Management

            12.6.3. By Country/Sub-region

    13. Middle East & Africa Focal Segmental Glomerulosclerosis Market Analysis and Forecast

        13.1. Introduction

        13.2. Key Findings

        13.3. Market Value Forecast, by Disease Type, 2017–2031

            13.3.1. Primary Focal Segmental Glomerulosclerosis

            13.3.2. Secondary Focal Segmental Glomerulosclerosis

        13.4. Market Value Forecast, by Disease Management, 2017–2031

            13.4.1. Diagnosis

                13.4.1.1. Kidney Biopsy

                13.4.1.2. Creatinine Test

                13.4.1.3. Others

            13.4.2. Treatment

                13.4.2.1. Drug Therapy

                13.4.2.2. Dialysis

                13.4.2.3. Kidney Transplant

        13.5. Market Value Forecast, by Country/Sub-region, 2017–2031

            13.5.1. GCC Countries

            13.5.2. South Africa

            13.5.3. Rest of Middle East & Africa

        13.6. Market Attractiveness Analysis

            13.6.1. By Disease Type

            13.6.2. By Disease Management

            13.6.3. By Country/Sub-region

    14. Competition Landscape

        14.1. Market Player - Competitive Matrix (by Tier and Size of Companies)

        14.2. Market Share Analysis, by Company (2022)

        14.3. Company Profiles

            14.3.1. Variant Pharmaceuticals, Inc.

                14.3.1.1. Company Overview

                14.3.1.2. Disease Type Portfolio

                14.3.1.3. SWOT Analysis

                14.3.1.4. Financial Overview

                14.3.1.5. Strategic Overview

            14.3.2. ChemoCentryx, Inc.

                14.3.2.1. Company Overview

                14.3.2.2. Disease Type Portfolio

                14.3.2.3. SWOT Analysis

                14.3.2.4. Financial Overview

                14.3.2.5. Strategic Overview

            14.3.3. Travere Therapeutics

                14.3.3.1. Company Overview

                14.3.3.2. Disease Type Portfolio

                14.3.3.3. SWOT Analysis

                14.3.3.4. Financial Overview

                14.3.3.5. Strategic Overview

            14.3.4. AbbVie, Inc.

                14.3.4.1. Company Overview

                14.3.4.2. Disease Type Portfolio

                14.3.4.3. SWOT Analysis

                14.3.4.4. Financial Overview

                14.3.4.5. Strategic Overview

            14.3.5. Novartis AG

                14.3.5.1. Company Overview

                14.3.5.2. Disease Type Portfolio

                14.3.5.3. SWOT Analysis

                14.3.5.4. Financial Overview

                14.3.5.5. Strategic Overview

            14.3.6. Pfizer, Inc.

                14.3.6.1. Company Overview

                14.3.6.2. Disease Type Portfolio

                14.3.6.3. SWOT Analysis

                14.3.6.4. Financial Overview

                14.3.6.5. Strategic Overview

            14.3.7. AstraZeneca plc.

                14.3.7.1. Company Overview

                14.3.7.2. Disease Type Portfolio

                14.3.7.3. SWOT Analysis

                14.3.7.4. Financial Overview

                14.3.7.5. Strategic Overview

            14.3.8. Sanofi S.A.

                14.3.8.1. Company Overview

                14.3.8.2. Disease Type Portfolio

                14.3.8.3. SWOT Analysis

                14.3.8.4. Financial Overview

                14.3.8.5. Strategic Overview

            14.3.9. GlaxoSmithKline plc.

                14.3.9.1. Company Overview

                14.3.9.2. Disease Type Portfolio

                14.3.9.3. SWOT Analysis

                14.3.9.4. Financial Overview

                14.3.9.5. Strategic Overview

            14.3.10. Teva Pharmaceutical Industries Ltd.

                14.3.10.1. Company Overview

                14.3.10.2. Disease Type Portfolio

                14.3.10.3. SWOT Analysis

                14.3.10.4. Financial Overview

                14.3.10.5. Strategic Overview

    List of Tables

    Table 01: Global Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Type, 2017–2031

    Table 02: Global Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Management, 2017–2031

    Table 03: Global Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Region, 2017–2031

    Table 04: North America Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Country, 2017–2031

    Table 05: North America Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Type, 2017–2031

    Table 06: North America Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Management, 2017–2031

    Table 07: Europe Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 8: Europe Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Type, 2017–2031

    Table 9: Europe Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Management, 2017–2031

    Table 10: Asia Pacific Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 11: Asia Pacific Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Type, 2017–2031

    Table 12: Asia Pacific Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Management, 2017–2031

    Table 13: Latin America Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 14: Latin America Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Type, 2017–2031

    Table 15: Latin America Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Management, 2017–2031

    Table 16: Middle East & Africa Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 17: Middle East & Africa Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Type, 2017–2031

    Table 18: Middle East & Africa Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Management, 2017–2031

    List of Figures

    Figure 01: Global Focal Segmental Glomerulosclerosis Market Size (US$ Mn) and Distribution (%), by Region, 2022 and 2031

    Figure 02: Global Focal Segmental Glomerulosclerosis Market Revenue (US$ Mn), by Disease Type, 2022

    Figure 03: Global Focal Segmental Glomerulosclerosis Market Value Share, by Disease Type, 2022

    Figure 04: Global Focal Segmental Glomerulosclerosis Market Revenue (US$ Mn), by Disease Management, 2022

    Figure 05: Global Focal Segmental Glomerulosclerosis Market Value Share, by Disease Management, 2022

    Figure 06: Global Focal Segmental Glomerulosclerosis Market Value Share, by Region, 2022

    Figure 07: Global Focal Segmental Glomerulosclerosis Market Value (US$ Mn) Forecast, 2017–2031

    Figure 08: Global Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Type, 2022 and 2031

    Figure 09: Global Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Type, 2023-2031

    Figure 10: Global Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Management, 2023 and 2031

    Figure 11: Global Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Management, 2023-2031

    Figure 12: Global Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Region, 2022 and 2031

    Figure 13: Global Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Region, 2023-2031

    Figure 14: North America Focal Segmental Glomerulosclerosis Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

    Figure 15: North America Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Country, 2023–2031

    Figure 16: North America Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Country, 2022 and 2031

    Figure 17: North America Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Type, 2022 and 2031

    Figure 18: North America Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Management, 2022 and 2031

    Figure 19: North America Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Type, 2023–2031

    Figure 20: North America Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Management, 2023–2031

    Figure 21: Europe Focal Segmental Glomerulosclerosis Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

    Figure 22: Europe Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 23: Europe Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 24: Europe Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Type, 2022 and 2031

    Figure 25: Europe Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Management, 2022 and 2031

    Figure 26: Europe Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Type, 2023–2031

    Figure 27: Europe Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Management, 2023–2031

    Figure 28: Asia Pacific Focal Segmental Glomerulosclerosis Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

    Figure 29: Asia Pacific Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 30: Asia Pacific Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 31: Asia Pacific Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Type, 2022 and 2031

    Figure 32: Asia Pacific Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Management, 2022 and 2031

    Figure 33: Asia Pacific Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Type, 2023-2031

    Figure 34: Asia Pacific Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Management, 2023–2031

    Figure 35: Latin America Focal Segmental Glomerulosclerosis Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

    Figure 36: Latin America Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 37: Latin America Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 38: Latin America Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Type, 2022 and 2031

    Figure 39: Latin America Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Management, 2022 and 2031

    Figure 40: Latin America Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Type, 2023–2031

    Figure 41: Latin America Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Management, 2023–2031

    Figure 42: Middle East & Africa Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

    Figure 43: Middle East & Africa Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 44: Middle East & Africa Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 45: Middle East & Africa Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Type, 2022 and 2031

    Figure 46: Middle East & Africa Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Management, 2022 and 2031

    Figure 47: Middle East & Africa Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Type, 2023–2031

    Figure 48: Middle East & Africa Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Management, 2023–2031

Copyright © Transparency Market Research, Inc. All Rights reserved